Overview

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
to determine safety, efficacy and tolerability of BI 1356 versus placebo
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Linagliptin